Interview with Dmitry Pogrebinsky, General Director, Protek
Published on 12 May 2020 by Anna Andriyanova
Adam Smith Conferences: How has the coronavirus pandemic affected the Russian pharmaceutical market?
Dmitry Pogrebinsky: The coronavirus pandemic has had a very serious impact on the Russian pharmaceutical market. In particular - uncertainty has been a huge factor affecting our work over the last few weeks. Specifically, the uncertainty over demand for pharmaceutical products both on the part of our clients, the retail sector, and on the part of the end consumer. Russians, as with populations in other countries, are especially susceptible to all the contradictory information about therapeutic and preventative treatments that is circulating through various channels, including the mass media. Information emerged that an anti-malarial drug had shown effectiveness in treating the coronavirus – and the product sold out in pharmacies.
Due to this uncertainty, the market is in a “fever” right now. Pressure is growing in all segments: in manufacturing, distribution, and retail. In Protek’s experience, I can say that in our segment the new conditions have resulted in an increased need for warehouse capacity and expedition. Until there is a clear understanding of which methods have proven effective in fighting the coronavirus (vaccines and medicines), this process will continue. And not only in Russia, but also in the global market.